This study demonstrates that patients with multi-hit TP53 represent the poorest prognostic group in MM, even when compared with patients with ≥ 2 other HR genetic abnormalities and independently of the number of prior lines of therapy. This evidence concerns the gene TP53 and Miyoshi myopathy.